Autologous hematopoietic progenitor cell transplantation for multiple Myeloma through an outpatient program

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1449-1462

  Martino, Massimo ^a   Montanari, Mauro ^b   Bruno, Benedetto ^c   Consol, Giuseppe ^a   Irrera, Giuseppe ^a   Messina, Giuseppe ^a   Offidani, Massimo ^b   Scortechini, Ilaria ^b   Moscato, Tiziana ^a   Fedele, Roberta ^a   Milone, Giuseppe ^d   Castagna, Luca ^e   Olivieri, Attilio ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Autologous hemopoietic progenitor cell transplantation; Health care resources; High dose melphalan; Multiple myeloma; Outpatient; Waiting lists

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DIMETHYL SULFOXIDE; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; BREAST CANCER; CAREGIVER; COST BENEFIT ANALYSIS; COST CONTROL; DIAGNOSIS RELATED GROUP; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HEALTH CARE COST; HEALTH PROGRAM; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OUTPATIENT CARE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REIMBURSEMENT; REVIEW; RISK ASSESSMENT; SOCIAL STATUS; TREATMENT RESPONSE; AMBULATORY CARE; AUTOTRANSPLANTATION; CLINICAL TRIAL (TOPIC); HEMATOPOIETIC STEM CELL TRANSPLANTATION; OUTPATIENT; PROCEDURES; PSYCHOLOGY;

AMBULATORY CARE; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; OUTPATIENTS; QUALITY OF LIFE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84867290609     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.707185     Document Type: Review

References (101)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. Cancer J Clin 2012;62(1):10-29
2. Durie BG, Salmon S. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17
4. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98
5. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
6. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005;106(13):4050-3
7. Laubach JP, Mitsiades CS, Mahindra A, et al. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw 2009;7:947-60
8. Jagannath S, Kyle RA, Palumbo A, et al. The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma Leuk 2010;10:28-43
9. Buckner CD, Fefer A, Bensinger WI, et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle experience. Eur J Haematol Suppl 1989;51:186-90
10. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica 2004;89(6):717-41
11. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410-51.23-25
12. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335(2):91-7
13. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348(19):1875-83
14. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106(12):3755-9
15. Fermand JP, Katsahian S, Divine M, et al. High dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23(36):9227-33
16. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24(6):929-36
17. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13(2):183-96
18. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349(26):2495-502
19. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. J Clin Oncol 2007;25(17):2434-41
20. Harousseau JL. Hematopoietic stem cell transplantation in multiple myeloma. J Natl Compr Canc Netw 2009;7:961-70
21. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54
22. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92(9):3131-6
23. Patriarca F, Petrucci MT, Bringhen S, et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82:93-105
24. Palumbo A, Rajkumar SV. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 2010;84:379-90
25. Blade J, Rosinol L, Cibeira MT, et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63
26. Bensinger W. Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 2008;26(3):480-92
27. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009;145(6):681-708
28. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114(27):5436-43
29. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011;117(23):6063-73
30. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2(8354):822-4
31. Jantunen E, Kuittinen T, Penttila K, et al. High-dose melphalan supported by autologous stem cell transplantation is safe and feasible in elderly myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006;37:917-22
32. Moreau P, Facon T, Leleu X, et al. Comparison of 200 mg/mq melphalan and 8 Gy total body irradiation plus 140 mg/mq melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the intergroup11 Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5
33. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46(4):485-501
34. Reece DE, Bredeson C, Perez WS, et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs ≥ 60 years of age. Bone Marrow Transplant 2003;32(12):1135-43
35. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995;13:1786-99
36. Blade J, Cibeira MT, Fernandez de Larrea C, Rosinol L. Multiple myeloma. Ann Oncol 2010;21(Suppl 7):vii313-9
37. Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma 2010;51(8):1424-43
38. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-77
39. Korbling M, Fliedner TM. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant 1996;17:675-8
40. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994;5:935-41
41. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxisin neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179-87
42. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxisfor fungal infections after bone marrow transplantation:a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52
43. Morabito F, Irrera G, Oliva E, et al. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Bone Marrow Transplant 2001;28:883-8
44. Fauser AA, Lang E, Kochling G, Daschner FD. A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow recipients. Infection 1994;22:271-5
45. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93
46. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 1994;38:2041-6
47. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9
48. Bodey GP, Hart J, Freireich EJ. Studies of a patient isolation unit and prophylactic antibiotics in cancer chemotherapy. Cancer 1968;22:1018-26
49. Anastasia A, Giglio F, Mazza R, et al. Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease. Leuk Lymphoma 2009;50:80-4
50. Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol 2006;24:4855-61
51. Ferrara F, Palmieri S, Viola A, et al. Outpatient-based peripheral blood stem cell transplantation for patients with multiple myeloma. Hematol J 2004;5:222-6
52. Freeman M, Vose J, Bennett C, et al. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995. Bone Marrow Transplant 1999;24:679-84
53. Frey P, Stinson T, Siston A, et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002;30:741-8
54. Gluck S, des Rochers C, Cano C, et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997;20:431-4
55. Jagannath S, Vesole DH, Zhang M, et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997;20:445-50
56. Leger C, Sabloff M, McDiarmid S, et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006;85:723-9
57. McDiarmid S, Hutton B, Atkins H, et al. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010;45:1220-6
58. Meisenberg BR, Miller WE, McMillan R, et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and non hematologic malignancies. J Clin Oncol 1997;15:11-17
59. Peters WP, Ross M, Vredenburgh JJ, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994;21(4 Suppl 7):25-31
60. Rizzo JD, Vogelsang GB, Krumm S, et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999;17:2811-18
61. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology 2000;14:171-85
62. Mehta J, Dulley FL. Outpatient or inpatient stem cell transplantation: patria est ubicunque est bene? Leuk Lymphoma 2009;50:3-5
63. Morabito F, Martino M, Stelitano C, et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002;87:1192-9
64. Montanari M, Scortechini I, Capelli D, et al. Feasibility of outpatient autologous stem cell transplantation in 238 patients with haematologic malignancy. Bone Marrow Transplant 2011; 46:S54
65. Kassar M, Medoff E, Seropian S, et al. Outpatient high-dose melphalan in multiple myeloma patients. Transfusion 2007;47:115-19
66. Ferrara F, Izzo T, Criscuolo C, et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2011;29:139-43
67. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997;20:451-8
68. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007;12:738-47
69. Amifostine: BC Cancer Agency". British Columbia Cancer Agency. 2006.Available from: http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/ amifostine.htm
70. Capelli D, Santini G, De Souza C, et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br J Haematol 2000;110(2):300-7
71. Phillips GL II, Bernstein SH, Liesveld JL, et al. A phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant 2011;17:1033-42
72. Olivieri A, Scortechini I, Capelli D, et al. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 2004;34:693-702
73. Faucher C, Le Corroller Soriano AG, Esterni B, et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant 2012;47(4):549-55
74. Frey P, Stinson T, Siston A, et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002;30:741-8
75. Weaver CH, Schwartzberg L, Zhen B, et al. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplant 1997;20:753-60
76. Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008;87:43-8
77. Geller RB, Dix SP, Belt RJ, et al. Minimum resource utilization for patients with breast cancer, lymphoma, or multiple myeloma undergoing mobilization and high-dose chemotherapy followed by peripheral blood stem cell transplants as outpatients [abstract]. Blood 1997;90:370
78. Gertz MA, Ansell SM, Dingli D, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83:1131-8
79. Westermann AM, Holtkamp MM, Linthorst GA, et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol 1999;10:511-17
80. Rodenhuis S, Westermann A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996;14:1473-83
81. Martino M, Pellicano' G, Moscato T, et al. At-home management of aplastic phase following high-dose melphalan and autologous haematopoietic stem cell transplantation for multiple myeloma patients: a pilot study. ASH Annual Meeting Abstracts. Blood 2011;118:21
82. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreductionfor the treatment of malignant and non-malignanthematologic diseases. Blood 1998;91:756-63
83. Subira M, Sureda A, Ancin I, et al. Allogeneic stem cell transplantation with reduced-intensity conditioning is potentially feasible as an outpatient procedure. Bone Marrow Transplant 2003;32(9):869-72
84. Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz-Arguelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant 2000;25:131-3
85. Nieto Y, Patton N, Hawkins T, et al. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biol Blood Marrow Transplant 2006;12:217-25
86. Martino M, Morabito F, Messina G, et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996;81:59-61
87. Syme R, Bewick M, Stewart D, et al. The role of depletion of dimethyl sulfoxide before autografting: on hematologic recovery, side effects, and toxicity. Biol Blood Marrow Transplant 2004;10:135-41
88. Moores KG. Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am J Health Syst Pharm 2007;64:717-22
89. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37(11):1031-5
90. Vokurka S, Bystricka E, Scudlova J, et al. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m (2) autologous hematopoietic stem cell transplantation. Eur J Oncol Nurs 2011;15(5):508-12
91. Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011(4):CD000978
92. Barosi G, Marchetti M, Alessandrino P, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 1999;23:719-25
93. Sonnenberg FA, Beck J.R. Markov models in medical decision making: a practical guide. Med Dec Making 1993;13:322-38
94. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol 2003;25(3):179-84
95. Mishra V, Andresen S, Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 2005;35:1149-53
96. Meisenberg BR, Ferran K, Hollenbach K, et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998;21:927-32
97. Summers N, Dawe U, Stewart DA. A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant 2000;26:389-95
98. Mackay M. Practical experience with bed occupancy management and planning systems: an Australian view. Health Care Manag Sci 2001;4(1):47-56
99. van Tiel FH, Harbers MM, Kessels AG, et al. Home care versus hospital care of patients and chemotherapy induced cytopenia. Ann Oncol 2005;16:195-05
100. Kurthaus M, Wolf HH, Kampfe D, et al. Ceftriaxone mono therapy in the treatment of low risk febrile neutropenia. Chemotherapy 1998;44:343-54
101. Karthaus M, Rosenthal C, Ganser A. Prophylaxis and treatmentof chemo- and radiotherapy-induced oral mucositis-are there new strategies? Bone Marrow Transplant 1999;1095-108